Poland is growing faster then other EU countries and there is good base to build a winning life science cluster. ±€5 bil in pharma/y, ±€1bil in medical devices/y, 8000 local life science companies, about 1000 Hospitals and 20k clinics or 6H beds /000 (2x than the USA and 1.5x then CH) is a good start. Bioengineering MSc degrees are issued in english in more than one University and this adds more skills and specialized staff in the market; however all this needs a boost as there is yet not enough concentration of interconnected businesses, free contractors, associated institutions and startup wins to evidence a clear self regeneration. Some of Poland new round of grants (±€5 bil /year in development) could help if intentionally directed to this sector and partially adapted to the special requirements life science early stage projects need to achieve commercialization.
A first “nexus” with foreign direct investments (FDI) was made in Poland launching an R&D center to develop a small non-invasive ear-VNS treatment of cognitive impairment degeneration / Alzheimer’s Disease @ Home. Animal studies are conducted in Lodz. .. http://pulsinnowacji.pb.pl/4638514,20557,ojciec-start-upow-inwestuje-w-polsce
opened new Poland Ventures offices in: Natolin 15, 92-703 Łódź, Poland
Makwa is in tight business contacts with Polish and Israeli technology managers to raise funds from BSD GROWTH a self managed fund based in Gibraltar. Our role will be as a GP running for FoF tenders in Poland while (if winners) use the BSD GROWTH Fund as a support investment vehicle (LP) to choose, manage and escort the targeted companies from as early as a post proof of concept (POC) stage well through the commercialisation stage into an exit.
Yigal Erlich, Adam Broncel and David Vita @ Bioforum in Lodz 2016